Skip to main content


Latest articles

11-04-2019 | Rheumatology | News | Article

‘Poor’ reporting of concomitant treatment in rheumatology trials

The use of concomitant medications that may influence outcomes is “poorly reported” in rheumatology trials, say researchers.

11-04-2019 | Rheumatology | News | Article

FDA approves romosozumab for fracture prevention in osteoporosis

Click through for more information on this announcement

10-04-2019 | Rheumatology | News | Article

ORAL Sequel demonstrates consistent long-term safety, efficacy profiles of tofacitinib

The Janus kinase inhibitor tofacitinib has demonstrated a consistent safety profile and sustained efficacy in rheumatoid arthritis patients over a maximum follow-up of 9.5 years, report the ORAL Sequel investigators.

09-04-2019 | Rheumatology | News | Article

Updated EULAR guidelines for lupus management issued

EULAR has published up-to-date recommendations for the management of systemic lupus erythematosus based on emerging evidence and expert opinion.

08-04-2019 | Rheumatology | News | Article

Biomarker panel may help differentiate PsA from osteoarthritis

A panel of four soluble biomarkers comprising markers of cartilage metabolism, metabolic syndrome, and inflammation could distinguish psoriatic arthritis from osteoarthritis, researchers report.

05-04-2019 | Rheumatology | News | Article

Beneficial effects of NSAIDs peak early in knee osteoarthritis

A meta-analysis of 72 randomized controlled trials including 26,424 participants with knee osteoarthritis suggests that the beneficial pain-relief effects of oral NSAIDs peak at 2 weeks, while minor adverse events begin to appear at 4 weeks.

04-04-2019 | Rheumatology | News | Article

OA, RA have similar disease burden at the time of diagnosis

Osteoarthritis is associated with a similar disease burden to rheumatoid arthritis at the time of first presentation, despite traditionally being perceived as a milder condition, researchers report.

03-04-2019 | Rheumatology | News | Article

Abatacept may not provoke respiratory events in RA patients with COPD

Individuals with rheumatoid arthritis (RA) and chronic obstructive pulmonary disease who are treated with abatacept do not have an elevated risk for adverse respiratory events relative to those given other biologics, real-world study results suggest.

02-04-2019 | Rheumatology | News | Article

Cardiovascular risk associated with conventional, biologic DMARDs characterized

Tocilizumab is associated with a lower risk for major adverse cardiovascular events than tumor necrosis factor inhibitors among patients with rheumatoid arthritis, whereas the use of conventional DMARDs may be linked to an elevated risk, researchers report.

01-04-2019 | Rheumatology | News | Article

Risk factors for dyspnea identified in RA patients

Older age, female sex, and poor functional status are significant predictors of dyspnea on exertion among patients with rheumatoid arthritis, researchers report.

29-03-2019 | Rheumatology | News | Article

FDA approves certolizumab pegol for nonradiographic axSpA

Click through for more detail on this approval

29-03-2019 | Rheumatology | News | Article

Benefits of sarilumab confirmed in Japanese RA patients

Adding sarilumab to methotrexate significantly improves the signs and symptoms of rheumatoid arthritis relative to placebo in Japanese patients with an inadequate response to methotrexate monotherapy, study findings indicate.

28-03-2019 | Rheumatology | News | Article

Support for stroke prevention strategies in SSc patients

Individuals with systemic sclerosis have an elevated risk for ischemic stroke after adjustment for traditional cardiovascular risk factors, study findings suggest.

27-03-2019 | Rheumatology | News | Article

Biologics may influence durability of yellow fever vaccine response in RA patients

Treatment with biologics in combination with conventional DMARDs is associated with a reduction in the duration of protective immunity induced by the 17DD yellow fever vaccine among patients with rheumatoid arthritis, research suggests.

26-03-2019 | Rheumatology | News | Article

EMA warns of increased risk for pulmonary embolism and death with higher dose of tofacitinib

Click through for further details on this safety alert

25-03-2019 | Rheumatology | News | Article

Infections tied to increased risk for Sjögren’s syndrome

Individuals with primary Sjögren’s syndrome are almost twice as likely to have experienced an infection requiring hospital care than those without, researchers report.

22-03-2019 | Rheumatology | News | Article

Deep learning algorithm shows promise for predicting RA outcomes

Findings from a proof-of-concept study suggest that deep learning models based on electronic health records may be a feasible approach for forecasting disease outcomes in people with rheumatoid arthritis.

21-03-2019 | Rheumatology | News | Article

Progressive skin fibrosis should trigger enhanced monitoring in dcSSc

Progressive skin fibrosis is significantly associated with worsening lung function and an increased risk for death among patients with diffuse cutaneous systemic sclerosis, an analysis of EUSTAR data shows.

20-03-2019 | Rheumatology | News | Article

RA disease activity linked to cognitive impairment

Rheumatoid arthritis patients with high disease activity are more likely to have cognitive impairment than those with less active disease, researchers report.

19-03-2019 | Rheumatology | News | Article

Almost half of RA patients relapse after TNF inhibitor discontinuation

Findings from a systematic review and meta-analysis suggest that nearly half of patients with rheumatoid arthritis in remission experience disease relapse after elective discontinuation of tumor necrosis factor inhibitors.

Image Credits